MET and renal carcinoma: Although aberrant c-Met and other RTK hyper-activation are the major drivers of renal cancer growth, recent reports clearly suggest an alarmingly high incidence of renal cancer in patients receiving calcineurin inhibitors (CNIs) as immunosuppressive therapy for the treatment of immune disorders or after having organ transplants19–21.